Full Text of SR0135 103rd General Assembly
SR0135 103RD GENERAL ASSEMBLY |
| | SR0135 | | LRB103 31164 ECR 57950 r |
|
| 1 | | SENATE RESOLUTION
| 2 | | WHEREAS, Breast cancer is among the most commonly | 3 | | diagnosed types of cancer and the second leading cause of | 4 | | cancer death among women in the United States; and
| 5 | | WHEREAS, Approximately 297,790 women will be diagnosed | 6 | | with breast cancer, and more than 43,000 will die with this | 7 | | malignancy in 2023; and
| 8 | | WHEREAS, Triple-Negative Breast Cancer (TNBC) is one of | 9 | | many forms of breast cancer and accounts for approximately 15 | 10 | | to 20% of all diagnosed invasive breast cancer cases in the | 11 | | United States; and
| 12 | | WHEREAS, In 2019, more than 53,700 new breast cancer cases | 13 | | in the United States were diagnosed as TNBC, with higher | 14 | | prevalence among younger women, Black and Hispanic women, | 15 | | women with type 2 diabetes or carrying excess weight in the | 16 | | abdomen area, and those with BRCA1 mutations; and
| 17 | | WHEREAS, Due to its aggressive behavior, TNBC grows | 18 | | quickly, is more likely to have spread at the time it is found, | 19 | | and is more likely to come back after treatment than other | 20 | | types of breast cancer; and
|
| | | SR0135 | - 2 - | LRB103 31164 ECR 57950 r |
|
| 1 | | WHEREAS, People diagnosed with metastatic TNBC have a less | 2 | | than 30% chance of surviving past five years; and
| 3 | | WHEREAS, TNBC cells do not contain, or are "negative for", | 4 | | three key receptors that medicines typically target in other | 5 | | types of breast cancer; therefore, limited treatment options | 6 | | that can be used to treat the cancer; and
| 7 | | WHEREAS, Patients with an early diagnosis can often be | 8 | | treated with chemotherapy, radiation, and surgery; however, | 9 | | the limited therapies available, which specifically address | 10 | | the management of TNBC, have made treating this disease a | 11 | | challenge for clinicians; and
| 12 | | WHEREAS, Recent innovation in targeted therapies have | 13 | | fueled advances in the fight against TNBC; and
| 14 | | WHEREAS, Studies have shown that TNBC disease-specific | 15 | | mortality rates are often higher if patients have Medicaid or | 16 | | Medicare or come from a lower socioeconomic status; compared | 17 | | with non-Hispanic white women, Black women are 48% less likely | 18 | | to receive guideline adherent care and have an approximate | 19 | | two-fold higher mortality incidence, resulting in a | 20 | | disproportionately higher risk of death from TNBC; and
| 21 | | WHEREAS, Advances in breast cancer screening and treatment |
| | | SR0135 | - 3 - | LRB103 31164 ECR 57950 r |
|
| 1 | | over the last few decades have reduced the overall breast | 2 | | cancer mortality rate, yet the disproportionate impact of TNBC | 3 | | on racial and ethnic minority communities raises | 4 | | considerations about the underlying determinants driving the | 5 | | disparities; and
| 6 | | WHEREAS, It is necessary to promote TNBC education to | 7 | | raise awareness about disease-related disparities and to | 8 | | tackle inequities within health care delivery, such as | 9 | | inadequate access to screening, diagnostic testing, and care | 10 | | to improve early detection and survival; therefore, be it
| 11 | | RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL | 12 | | ASSEMBLY OF THE STATE OF ILLINOIS, that we declare the month of | 13 | | March 2023 as Triple-Negative Breast Cancer Awareness Month in | 14 | | the State of Illinois; and be it further
| 15 | | RESOLVED, That we support legislation to reduce | 16 | | Triple-Negative Breast Cancer (TNBC) disparities in early | 17 | | detection and survival by improving education and awareness | 18 | | through health promotion initiatives targeting underserved | 19 | | communities that are disproportionately impacted, which will | 20 | | help in ensuring equitable access and affordability of breast | 21 | | cancer screening, genetic counseling, and diagnostic testing, | 22 | | promoting cultural sensitivity and workforce diversity | 23 | | policies in health care provider training, and guaranteeing |
| | | SR0135 | - 4 - | LRB103 31164 ECR 57950 r |
|
| 1 | | timely patient access to clinically appropriate treatment | 2 | | options identified in the National Comprehensive Cancer | 3 | | Network (NCCN) guidelines; and be it further
| 4 | | RESOLVED, That additional legislative provisions should be | 5 | | examined to safeguard affordable, continuous, and equitable | 6 | | patient access to TNBC-related care, services, and medicines | 7 | | along the entire continuum of care.
|
|